42.05
price up icon3.72%   1.433
 
loading
Precedente Chiudi:
$40.62
Aprire:
$41.66
Volume 24 ore:
2.21M
Relative Volume:
1.06
Capitalizzazione di mercato:
$5.20B
Reddito:
$692.26M
Utile/perdita netta:
$-512.41M
Rapporto P/E:
-9.9182
EPS:
-4.24
Flusso di cassa netto:
$-274.36M
1 W Prestazione:
+10.87%
1M Prestazione:
-10.07%
6M Prestazione:
+18.61%
1 anno Prestazione:
+55.46%
Intervallo 1D:
Value
$39.70
$42.52
Intervallo di 1 settimana:
Value
$37.73
$42.52
Portata 52W:
Value
$20.14
$52.92

Guardant Health Inc Stock (GH) Company Profile

Name
Nome
Guardant Health Inc
Name
Telefono
855-698-8887
Name
Indirizzo
3100 HANOVER STREET, PALO ALTO
Name
Dipendente
2,021
Name
Cinguettio
@guardanthealth
Name
Prossima data di guadagno
2024-11-06
Name
Ultimi documenti SEC
Name
GH's Discussions on Twitter

Confronta GH con altri titoli

Azioni Prezzo Cap. di mercato Reddito Reddito netto Flusso di cassa EPS
Diagnostics & Research icon
GH
Guardant Health Inc
41.97 4.85B 692.26M -512.41M -274.36M -4.24
Diagnostics & Research icon
TMO
Thermo Fisher Scientific Inc
395.74 152.34B 42.90B 6.52B 6.72B 17.05
Diagnostics & Research icon
DHR
Danaher Corp
188.94 135.39B 23.82B 3.77B 4.90B 5.15
Diagnostics & Research icon
IDXX
Idexx Laboratories Inc
514.39 41.54B 3.93B 894.97M 837.70M 10.82
Diagnostics & Research icon
A
Agilent Technologies Inc
110.84 31.59B 6.63B 1.17B 1.19B 4.05
Diagnostics & Research icon
IQV
Iqvia Holdings Inc
138.79 24.31B 15.50B 1.33B 2.16B 7.34

Guardant Health Inc Stock (GH) Upgrades & Downgrades

Data Azione Analista Modifica della valutazione
2025-04-10 Iniziato Mizuho Outperform
2025-01-23 Iniziato Barclays Overweight
2024-06-28 Aggiornamento Guggenheim Neutral → Buy
2024-06-03 Ripresa Jefferies Buy
2024-04-24 Ripresa Craig Hallum Buy
2023-12-14 Iniziato Guggenheim Neutral
2023-12-13 Iniziato Wolfe Research Peer Perform
2023-11-13 Aggiornamento Raymond James Mkt Perform → Outperform
2023-09-28 Iniziato Bernstein Outperform
2023-09-27 Aggiornamento Piper Sandler Neutral → Overweight
2023-07-05 Ripresa JP Morgan Overweight
2023-05-26 Aggiornamento Citigroup Neutral → Buy
2023-05-05 Iniziato UBS Buy
2023-03-09 Downgrade Citigroup Buy → Neutral
2023-01-05 Iniziato Scotiabank Sector Outperform
2022-11-01 Downgrade Piper Sandler Overweight → Neutral
2022-10-19 Iniziato Craig Hallum Buy
2022-10-06 Iniziato Stephens Overweight
2022-08-25 Iniziato Credit Suisse Outperform
2022-06-03 Iniziato Piper Sandler Overweight
2022-04-28 Ripresa BTIG Research Buy
2022-02-24 Reiterato Canaccord Genuity Buy
2022-02-24 Reiterato Citigroup Buy
2022-02-24 Reiterato Cowen Outperform
2022-02-24 Reiterato Morgan Stanley Overweight
2022-02-24 Reiterato SVB Leerink Outperform
2022-02-24 Reiterato Stifel Buy
2022-02-24 Reiterato Wells Fargo Overweight
2021-10-15 Ripresa Cowen Outperform
2021-06-15 Iniziato Raymond James Mkt Perform
2021-06-03 Iniziato Goldman Buy
2021-05-25 Iniziato Wells Fargo Overweight
2021-01-11 Iniziato Stifel Buy
2020-09-09 Iniziato Morgan Stanley Overweight
2020-06-12 Iniziato BTIG Research Buy
2020-02-21 Iniziato Guggenheim Buy
2020-01-07 Iniziato Citigroup Buy
2019-08-07 Reiterato Canaccord Genuity Buy
2019-04-16 Iniziato Canaccord Genuity Buy
2019-04-10 Aggiornamento BofA/Merrill Neutral → Buy
2019-02-28 Reiterato BofA/Merrill Neutral
2018-10-29 Iniziato BofA/Merrill Neutral
2018-10-29 Iniziato JP Morgan Overweight
2018-10-29 Iniziato William Blair Outperform
Mostra tutto

Guardant Health Inc Borsa (GH) Ultime notizie

pulisher
11:25 AM

Raymond James reaffirms Guardant Health stock rating after NCCN update - Investing.com Australia

11:25 AM
pulisher
10:30 AM

National Comprehensive Cancer Network (NCCN) Updates Colorectal Cancer Screening Guidelines to Include Shield Blood-Based Screening - BioSpace

10:30 AM
pulisher
08:53 AM

Guardant Health (GH) Gains NCCN Approval for Colorectal Cancer Test | GH Stock News - GuruFocus

08:53 AM
pulisher
08:42 AM

Guardant Health Announced the results of the Serena-6 Phase III Trial - marketscreener.com

08:42 AM
pulisher
08:15 AM

National Comprehensive Cancer Network (NCCN) Updates Colorectal Cancer Screening Guidelines to Include Shield Blood-Based Screening | GH Stock News - GuruFocus

08:15 AM
pulisher
08:12 AM

SERENA-6 Phase III Trial Demonstrates Clinical Value of Guardant360 CDx Test to Detect Emergence of Endocrine Resistance and Inform a Switch in Therapy Before Radiological Disease Progression in Advanced Breast Cancer - BioSpace

08:12 AM
pulisher
12:30 PM

Liquid Biopsy Market for Cancer Detection, cfDNA & CTC Analysis | - openPR.com

12:30 PM
pulisher
Jun 01, 2025

Guardant Health (GH) Reveals Key Insights on Colon Cancer Recurrence | GH Stock News - GuruFocus

Jun 01, 2025
pulisher
May 31, 2025

Guardant Health, Inc. (GH)’s ctDNA Test Predicts Colon Cancer Recurrence Risk in Stage III Patients - Insider Monkey

May 31, 2025
pulisher
May 31, 2025

In Largest Molecular Residual Disease (MRD) Study in Colon Cance - GuruFocus

May 31, 2025
pulisher
May 31, 2025

In Largest Molecular Residual Disease (MRD) Study in Colon Cancer, Guardant Reveal Testing Prior to Chemotherapy Provides Robust Stratification for Risk of Disease Recurrence and Survival to Enable Timely Treatment Decisions - Yahoo Finance

May 31, 2025
pulisher
May 31, 2025

Guardant Health, Inc. (GH) Expands Liquid Biopsy to Pinpoint Tumor Origins and Biomarkers - MSN

May 31, 2025
pulisher
May 30, 2025

Guardant Health Inc (GH) Stock Price Up 5.11% on May 30 - GuruFocus

May 30, 2025
pulisher
May 30, 2025

Upcoming Chicago Meeting for Guardant Health (GH) Investors | GH Stock News - GuruFocus

May 30, 2025
pulisher
May 30, 2025

How Delfi Therapeutics plans to make liquid biopsies more accessible - The Business Journals

May 30, 2025
pulisher
May 28, 2025

Guardant Health Inc (GH) Trading Down 3.27% on May 28 - GuruFocus

May 28, 2025
pulisher
May 28, 2025

Guardant Health, Inc. (NASDAQ:GH) Shares Sold by Nuveen Asset Management LLC - Defense World

May 28, 2025
pulisher
May 28, 2025

Guardant Health enhances cancer blood test capabilities By Investing.com - Investing.com South Africa

May 28, 2025
pulisher
May 28, 2025

Firing on All Cylinders: Guardant Health (NASDAQ:GH) Q1 Earnings Lead the Way - Yahoo Finance

May 28, 2025
pulisher
May 27, 2025

Guardant Health enhances cancer blood test capabilities - Investing.com Australia

May 27, 2025
pulisher
May 27, 2025

Guardant Health Introduces Nearly a Dozen Groundbreaking Smart Liquid Biopsy Applications for Guardant360 Liquid Test | GH Stock News - GuruFocus

May 27, 2025
pulisher
May 27, 2025

Guardant Health Introduces Nearly a Dozen Groundbreaking Smart Liquid Biopsy Applications for Guardant360 Liquid Test - Eagle-Tribune

May 27, 2025
pulisher
May 25, 2025

Ameriprise Financial Inc. Purchases 76,124 Shares of Guardant Health, Inc. (NASDAQ:GH) - Defense World

May 25, 2025
pulisher
May 23, 2025

New Tests Promise to Reveal the Secrets in Your Blood - WSJ

May 23, 2025
pulisher
May 23, 2025

Investor Attention Turns to Biotech as Traditional Cancer Research Models Strain - Baystreet.ca

May 23, 2025
pulisher
May 23, 2025

Guardant Health and Collaborators to Present Over 19 Studies Demonstrating Role of Liquid Biopsy in Advancing Precision Oncology at 2025 ASCO Annual Meeting - BioSpace

May 23, 2025
pulisher
May 22, 2025

(GH) Technical Data - news.stocktradersdaily.com

May 22, 2025
pulisher
May 22, 2025

Guardant Health and Collaborators to Present Over 19 Studies Demonstrating Role of Liquid Biopsy in Advancing Precision Oncology at 2025 ASCO Annual Meeting | GH Stock News - GuruFocus

May 22, 2025
pulisher
May 21, 2025

Guardant Health, Evolent Health, Charles River Laboratories, Avantor, and Lumen Stocks Trade Down, What You Need To Know - Yahoo Finance

May 21, 2025
pulisher
May 21, 2025

Guardant Health (GH) introduces IHC Solid Tumor Testing to its Portfolio - Insider Monkey

May 21, 2025
pulisher
May 21, 2025

Guardant Health Launches Immunohistochemistry Testing for Solid Tumors - marketscreener.com

May 21, 2025
pulisher
May 21, 2025

Guardant Health Introduces Comprehensive Immunohistochemistry Testing for Solid Tumors - BioSpace

May 21, 2025
pulisher
May 21, 2025

Guardant Health, Inc. Introduces Comprehensive Immunohistochemistry Testing for Solid Tumors - marketscreener.com

May 21, 2025
pulisher
May 21, 2025

Guardant Health Introduces Comprehensive Immunohistochemistry Testing for Solid Tumors | GH Stock News - GuruFocus

May 21, 2025
pulisher
May 21, 2025

Guardant Health expands oncology testing with IHC suite - Investing.com

May 21, 2025
pulisher
May 20, 2025

Guardant Health unveils new cancer risk test By Investing.com - Investing.com South Africa

May 20, 2025
pulisher
May 20, 2025

Guardant Health Introduces Hereditary Cancer Testing to Identify Inherited Predispositions to Certain Types of Cancer - BioSpace

May 20, 2025
pulisher
May 20, 2025

Guardant Health Introduces Hereditary Cancer Testing to Identify Inherited Predispositions to Certain Types of Cancer | GH Stock News - GuruFocus

May 20, 2025
pulisher
May 20, 2025

Guardant Health unveils new cancer risk test - Investing.com

May 20, 2025
pulisher
May 16, 2025

Guardant Health: A Promising Player in the Liquid Biopsy Market - The Globe and Mail

May 16, 2025
pulisher
May 16, 2025

Guardant Health: A Promising Player In The Liquid Biopsy Market - Barchart.com

May 16, 2025
pulisher
May 16, 2025

New Horizons in Cancer Genetic Profiling Market Exploring - openPR.com

May 16, 2025

Guardant Health Inc Azioni (GH) Dati Finanziari

Reddito

loading

Reddito netto

loading

Flusso di cassa

loading

EPS

loading

Guardant Health Inc Azioni (GH) insider trading

Commercio interno Relazione Data Transazione Costo #Azioni Valore ($) #Azioni Totale
Tariq Musa
Director
May 15 '25
Option Exercise
0.00
250
0
3,595
POTTER MYRTLE S
Director
May 15 '25
Option Exercise
0.00
68
0
14,063
EAGLE CRAIG
Chief Medical Officer
May 15 '25
Option Exercise
0.00
3,718
0
36,318
Chudova Darya
Chief Technology Officer
May 15 '25
Option Exercise
0.00
8,705
0
83,210
diagnostics_research DGX
$174.50
price up icon 0.81%
diagnostics_research WAT
$343.98
price down icon 1.51%
diagnostics_research LH
$246.59
price down icon 1.03%
$158.47
price up icon 0.52%
diagnostics_research MTD
$1,138.41
price down icon 1.54%
diagnostics_research IQV
$139.15
price down icon 0.86%
Capitalizzazione:     |  Volume (24 ore):